Boston Scientific Corporation (NYSE:BSX) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 8:01 AM ET
Company Participants
Michael Mahoney – Chairman and Chief Executive Officer
Kenneth Stein – Senior Vice President and Global Chief Medical Officer
Conference Call Participants
Lee Hambright – Sanford C. Bernstein & Co., LLC
Lee Hambright
Okay. Thanks, everybody, for coming. I’m Lee Hambright, U.S. medtech analyst at Bernstein. We are very pleased to host Boston Scientific today. We’ve got Chairman and CEO, Mike Mahoney; and Chief Medical Officer, Dr. Ken Stein. Thanks so much, guys, for being here.
Michael Mahoney
Good morning. Pleasure.
Lee Hambright
For those of you in the audience, if you would like to ask a question, you could submit it via the pigeonhole tool, and I will try to work in as many as I can here. So Mike, kicking off here, 2024 was another incredible year for Boston Scientific with 16.5% organic growth, 22% EPS growth. You had a great start to 2025 with 18% organic and 34% EPS growth in Q1, which sets you up for a strong year. Maybe you could just kick us off with a few thoughts on the state of the business at Boston Scientific.
Michael Mahoney
Great. Thanks for having us. And Dr. Stein, thanks for coming as well. Just very proud of the very high execution of the company for many years in a row. And as you know, our aim is to be the highest – we’re a medtech company. I think we likely were last year, hopefully, this year, and maybe the year before that. And our goal is to do that for the next five years. And we spend time every day at hitting our near-term commitments and investing to have a differentiated future. And we can talk about that with our portfolio. But that’s our 100% focus of the company, and we’re off to a really
#Boston #Scientific #Corporation #BSX #Bernstein #41st #Annual #Strategic #Decisions #Conference #Transcript